USFDA informs Biocon Biologics, Mylan of deferred action on Avastin biosimilar license application

"To complete the application, the agency noted that an inspection of the manufacturing facility is required as a part of the standard review process. However, due to restrictions on travel related to COVID-19, the agency is unable to conduct an inspection during the current review cycle. We await the dates for the inspection," Biocon said in a regulatory filing.

from Industry-Economic Times https://ift.tt/3nQdgXE
via IFTTT